Who are IL-2 pre-treated CD19 cells's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LONCASTUXIMAB TESIRINE, Uplizna, BLINATUMOMAB, Blincyto, SCT800 and Daratumumab, MONJUVI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/il-2-pre-treated-cd19-cells.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

IL-2 pre-treated CD19 cells — Competitive Intelligence Brief

IL-2 pre-treated CD19 cells (IL-2 pre-treated CD19 cells) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adoptive cell therapy. Area: Oncology.

marketed Adoptive cell therapy CD19 Oncology Biologic Live · refreshed every 30 min

Target snapshot

IL-2 pre-treated CD19 cells (IL-2 pre-treated CD19 cells) — jiangjingting. IL-2 pre-treated CD19-targeted cells enhance immune recognition and elimination of CD19-expressing B-cell malignancies through cytokine-primed cellular immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IL-2 pre-treated CD19 cells TARGET	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Uplizna	INEBILIZUMAB	Viela Bio	marketed	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
BLINATUMOMAB	BLINATUMOMAB		marketed		CD19, CD3	2014-01-01
Blincyto	blinatumomab	Amgen	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	2014-01-01
SCT800 and Daratumumab	SCT800 and Daratumumab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Bispecific T-cell engager (SCT800); CD38-targeting monoclonal antibody (Daratumumab)	CD19 and CD3 (SCT800); CD38 (Daratumumab)
MONJUVI	TAFASITAMAB-CXIX	MORPHOSYS US INC	marketed		B-lymphocyte antigen CD19

Recent regulatory actions (last 90 days)

2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adoptive cell therapy class)

Chuan An Biotechnology Co., Ltd. · 1 drug in this class
jiangjingting · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IL-2 pre-treated CD19 cells — Competitive Intelligence Brief. https://druglandscape.com/ci/il-2-pre-treated-cd19-cells. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab